Norephrine
PreclinicalSmall molecule
Norephrine is one of 11 small molecule programs targeting Chronic Liver Failure. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Chronic Liver Failure
#DrugCompanyPhaseTrials
1Mozobil
GGenzyme, a Sanofi Company
Approved
Coreg
Akero TherapeuticsPreclinical
Chronulac
SSolvay Pharmaceuticals
Preclinical
Osmitrol
BB. Braun Medical Inc.
Preclinical
Glypressin
MMallinckrodt
Preclinical
Plasma Exchange
SanofiPreclinical
Viread
GSKPreclinical
Standard Medical Therapy
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Albumin
LLaboratoire français de Fractionnement et de Biotechnologies
Preclinical
High Volume Plasma Exchange
IInstitute of Liver and Biliary Sciences, India
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Liver Failure1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Norephrine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details